证券代码：870656 证券简称：海昇药业 公告编号：2024-067 3.会议召开方式：现场方式 4.发出董事会会议通知的时间和方式：2024 年 5 月 10 日以书面和通讯方式 发出 5.会议主持人：董事长叶山海先生 浙江海昇药业股份有限公司 第三届董事会第十六次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 5 月 16 日 2.会议召开地点：衢州市高新技术产业园区华阳路 36 号二楼会议室 6.会议列席人员：公司监事、高级管理人员 7.召开情况合法、合规、合章程性说明： 本次董事会会议召集、召开、议案审议程序等方面符合有关法律、行政法规、 部门规章、规范性文件和公司章程的规定。 （二）会议出席情况 会议应出席董事 6 人，出席和授权出席董事 6 人。 二、议案审议情况 （一）审议通过《关于使用部分闲置募集资金进行现金管理的议案》 1.议案内容： 具体内容详见公司于 2024 年 5 月 17 日在北京证券 ...

证券代码：870656 证券简称：海昇药业 公告编号：2024-071 一、会议召开基本情况 （一）股东大会届次 本次会议为 2024 年第二次临时股东大会。 （二）召集人 本次股东大会的召集人为董事会。 （三）会议召开的合法性、合规性 浙江海昇药业股份有限公司 关于召开 2024 年第二次临时股东大会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 召开本次会议的议案己于 2024 年 5 月 16 日经公司第三届董事会第十六次会 议审议通过。本次股东大会的召开符合有关法律、行政法规、部门规章、规范性 文件和公司章程，无需其他相关部门批准或履行其他程序。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 公司同一股东只能选择现场投票、网络投票中的一种方式，如果同一表决 权出现重复投票表决，以第一次投票表决结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2024 年 6 月 3 日 14:00。 2、网络投票起止时间：2024 年 6 月 2 日 1 ...

证券代码：870656 证券简称：海昇药业 公告编号：2024-070 浙江海昇药业股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 委托理财概述 （一） 委托理财目的 基于公司经营稳定，财务状况稳健，有较充裕的资金及有效的风险控制制度， 在确保公司正常经营活动资金需求的前提下，公司拟使用部分闲置自有资金进行 现金管理，以提高资金使用效率和收益，为公司股东谋取更好的回报。 （二） 委托理财金额和资金来源 公司拟进行的现金管理的金额不超过人民币 1 亿元（含本数），资金来源为 公司闲置自有资金。在上述额度内，资金可以循环滚动使用，委托理财取得的收 益可进行再投资，再投资的金额不包含在上述额度以内。 （三） 委托理财方式 本次现金管理事项不构成关联交易。 二、 决策与审议程序 2024 年 5 月 16 日召开第三届董事会第十六次会议、第三届监事会第十五次 会议，审议通过《关于使用闲置自有资金进行现金管理的议案》；该事项尚需提 交公司股东大会审议。 ...

证券代码：870656 证券简称：海昇药业 公告编号：2024-069 浙江海昇药业股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 2024 年 1 月 24 日，浙江海昇药业股份有限公司发行普通股 20,000,000 股， 发行方式为向不特定合格投资者公开发行，发行价格为 19.90 元/股，募集资金 总额为 398,000,000.00 元，实际募集资金净额为 398,000,000.00 元，到账时间 为 2024 年 1 月 26 日。公司因行使超额配售选择权取得的募集资金净额为 356,461,824.53 元，到账时间为 2024 年 1 月 26 日。 二、募集资金使用情况 （一）募集资金使用情况和存储情况 截至 2024 年 4 月 30 日，公司上述发行股份的募集资金使用情况具体如下： 单位：元 | 序号 | 募集资金用 | 实施 | 募集资金计划 | 累计投入募集 | 投入进度（%） （3）=（2）/ ...

2023 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 浙江海昇药业股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日在北 京证券交易所指定信息披露平台（www.bse.cn）披露了《2023 年年度报告》（公 告编号：2024-055）。为方便广大投资者更深入了解公司 2023 年年度经营业绩的 具体情况，加强与投资者的互动交流，公司拟召开 2023 年年度报告业绩说明会。 证券代码：870656 证券简称：海昇药业 公告编号：2024-066 浙江海昇药业股份有限公司 二、 说明会召开的时间、地点 （一）会议召开时间：2024 年 5 月 17 日（星期五）15：00-17：00。 （二）会议召开地点 本次业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者 关系互动平台"（https://ir.p5w.net）参与本次业绩说明会。 三、 参加人员 公司董事长、总经理：叶山海先生 公司财务负责人：黎文辉先生 公司董事会秘书： ...

Financial Performance - In 2023, the company's operating revenue was RMB 215,101,819.65, a decrease of 18.65% compared to RMB 264,415,476.77 in 2022[25]. - The net profit attributable to shareholders was RMB 84,755,693.84, down 24.78% from RMB 112,680,976.01 in the previous year[25]. - The gross profit margin for 2023 was 52.67%, slightly up from 52.47% in 2022[25]. - The basic earnings per share decreased by 25.00% to 1.41 from 1.88 in 2022[25]. - The weighted average return on equity was 32.45%, down from 46.77% in 2022[25]. - Operating cash flow decreased by 38.35% to ¥59,881,421.65 compared to 2022[27]. - The company's cash and cash equivalents decreased by 27.91% to ¥101.38 million, down from ¥140.63 million at the end of 2022[46]. - The accounts receivable turnover rate decreased to 8.12 from 15.40 in the previous year[28]. - The company's operating costs for 2023 were approximately ¥101.82 million, a decrease of 18.99% from ¥125.69 million in 2022[52]. - The company experienced a 40.91% reduction in financial expenses, which amounted to -¥4.73 million in 2023 compared to -¥8.01 million in 2022[52]. Capital and Investments - The company successfully raised RMB 398,000,000.00 through the issuance of 20 million shares at a price of RMB 19.90 each[21]. - After the capital increase, the company's registered capital is now RMB 80,000,000.00[21]. - Total assets increased by 6.03% to ¥307,375,267.23 compared to the end of 2022[27]. - Total liabilities decreased by 27.96% to ¥22,982,422.60 compared to the end of 2022[27]. - The company has committed to continuous innovation and market adaptation to prevent overcapacity and underperformance in fundraising projects[91]. Research and Development - R&D expenditure amounted to ¥9,034,133.57, representing 4.20% of operating revenue, up from 3.62% in the previous year[68]. - The company has six patents, all of which are invention patents, an increase from three in the previous year[69]. - The company invested a total of ¥6,600,000 in R&D during the reporting period, focusing on optimizing existing raw materials and developing new products[178]. - The top five R&D projects include the synthesis of DX raw materials with an investment of ¥600,828.28, XP raw materials with ¥1,139,958.60, and SMM raw materials with ¥2,441,638.58, all currently in the pilot stage[180]. - The company has achieved breakthroughs in the synthesis processes of SMM and SDM raw materials, significantly improving quality, yield, and cost[178]. Market and Industry Outlook - The domestic veterinary drug market is projected to reach ¥1,395.72 billion by 2027, with a compound annual growth rate of 12.56%[44]. - The veterinary drug industry is experiencing a growth phase due to the shift towards intensive farming practices, increasing the demand for veterinary pharmaceuticals[168]. - The global population is projected to reach 8.5 billion by 2030, with an increasing demand for pharmaceuticals driven by an aging population, thereby expanding the market for raw materials[170]. - The company is positioned to benefit from national policies promoting the green development of the pharmaceutical industry, which supports high-quality growth[166]. Environmental and Social Responsibility - The company has implemented a comprehensive wastewater treatment system, ensuring compliance with the "Comprehensive Wastewater Discharge Standard" (GB8978-1996) and other relevant regulations[75]. - The company has established online monitoring systems for wastewater discharge, tracking key indicators such as flow rate, pH, COD, and ammonia nitrogen[75]. - The company maintains a strong commitment to corporate social responsibility, including environmental protection and employee welfare[74]. - The company adheres to the "resource utilization, reduction, and harmlessness" principle for solid waste management, with hazardous waste being disposed of by qualified professional institutions[79]. Corporate Governance and Compliance - The company has established a governance structure that includes a board of directors with two independent directors, ensuring compliance with legal requirements[190]. - The company has implemented a system to ensure all shareholders can exercise their rights equally and has provided online voting options for shareholder meetings[191]. - The company has established a responsibility accountability system for significant errors in annual reports[189]. - The company has complied with all legal regulations regarding hazardous chemicals and has established relevant systems and facilities[186]. Shareholder and Stock Management - The company has ongoing commitments related to share lock-up and reduction, with a commitment period of 12 months from the public offering date[98]. - If the stock price falls below the offering price for 20 consecutive trading days, the lock-up period will be extended by 6 months[99]. - The company has committed to ensuring that any share reductions after the lock-up period will not be below the offering price[101]. - The company has approved a stock price stabilization plan, which includes measures such as share buybacks and increases by major shareholders if certain conditions are met[104]. Risk Management - The company is facing increased production costs due to stricter environmental regulations, which may lead to the elimination of non-compliant enterprises in the industry[87]. - The company is actively seeking strong partners to develop its generic drug business, aiming to enrich its existing product structure[86]. - The company has established a warning mechanism for raw material price changes to manage the risk of rising costs affecting profitability[90]. - Approximately 50% of the company's exports are subject to foreign exchange rate fluctuations, which may lead to potential exchange losses as the company expands overseas[88].

Financial Performance - Net profit attributable to shareholders decreased by 20.81% to ¥16,766,047.65 for the first quarter of 2024 [12]. - Operating revenue for the first quarter of 2024 was ¥41,910,557.19, a decrease of 27.50% year-on-year [12]. - Total operating revenue for Q1 2024 was CNY 41,910,557.19, a decrease from CNY 57,808,751.06 in Q1 2023, representing a decline of approximately 27.5% [30]. - Net profit for Q1 2024 was CNY 16,766,047.65, compared to CNY 21,172,619.70 in Q1 2023, reflecting a decrease of approximately 20.9% [31]. - Basic and diluted earnings per share for Q1 2024 were both CNY 0.21, down from CNY 0.35 in Q1 2023 [32]. - Total operating costs for Q1 2024 were CNY 22,625,437.43, down from CNY 32,709,750.84 in Q1 2023, indicating a reduction of about 30.8% [30]. - Research and development expenses for Q1 2024 were CNY 1,954,621.71, down from CNY 2,443,522.94 in Q1 2023, indicating a decrease of about 20% [30]. Assets and Liabilities - Total assets increased by 120.20% to ¥676,846,394.12 compared to the end of last year [12]. - The company reported a total of 529,409,707.17 CNY in current assets as of March 31, 2024, compared to 178,234,543.26 CNY at the end of 2023, indicating a significant increase [28]. - Total liabilities decreased to CNY 19,038,102.45 in 2024 from CNY 22,982,422.60 in 2023, a reduction of about 17.5% [30]. - The company's total liabilities to assets ratio remained low at 2.81% [12]. - Shareholders' equity rose significantly to CNY 657,808,291.67 in 2024 from CNY 284,392,844.63 in 2023, an increase of approximately 131.5% [30]. Cash Flow - Cash flow from operating activities decreased by 67.06% to ¥4,427,962.93 compared to the same period last year [12]. - Operating cash flow for Q1 2024 was ¥4,427,962.93, a decrease of 67.9% compared to ¥13,442,875.98 in Q1 2023 [33]. - Total cash inflow from operating activities was ¥32,511,620.00, down 27.8% from ¥44,962,256.35 in the same period last year [33]. - Cash inflow from other operating activities increased to ¥2,150,574.17, up 194.3% from ¥732,813.37 in Q1 2023 [33]. - Cash and cash equivalents increased by 348.50% to ¥454,706,743.51 due to fundraising [13]. - The cash and cash equivalents at the end of Q1 2024 totaled ¥454,706,743.51, significantly up from ¥140,091,972.99 at the end of Q1 2023 [34]. - Cash outflow from operating activities decreased to ¥28,083,657.07, a reduction of 10.3% compared to ¥31,519,380.37 in Q1 2023 [33]. - Investment activities resulted in a net cash outflow of ¥10,322,508.33, compared to a net outflow of ¥2,531,664.83 in Q1 2023 [34]. - Cash inflow from financing activities was ¥367,150,000.00, with a net cash flow of ¥358,978,400.00 after outflows [34]. - The company experienced a positive impact of ¥240,089.75 from exchange rate fluctuations on cash and cash equivalents [34]. Shareholder Information - The number of shares increased by 33.33% to 80,000,000 due to a public offering [13]. - The top five shareholders collectively hold 80.0739% of the company's shares, with the largest shareholder owning 24.75% [21]. - The company has no shareholders with pledged or judicially frozen shares, indicating a stable ownership structure [22]. - The company has not issued any preferred shares, simplifying its capital structure [22]. Compliance and Governance - The company has not engaged in any litigation or arbitration matters during the reporting period, ensuring compliance and stability [24]. - There were no significant related party transactions or external guarantees reported, maintaining financial integrity [24]. - Non-recurring gains and losses totaled ¥146,346.95, with a net amount after tax of ¥124,394.91 [16]. - The company reported a credit impairment loss of CNY -164,580.54 in Q1 2024, compared to CNY -586,378.93 in Q1 2023, showing an improvement in credit quality [31]. Market Position - The company is actively expanding its market presence, as indicated by the increase in cash reserves and accounts receivable, positioning itself for future growth [28]. - Cash and cash equivalents increased to 454,706,743.51 CNY from 101,382,799.16 CNY, reflecting a growth of approximately 347% [28]. - Accounts receivable rose to 35,652,371.95 CNY from 31,942,433.19 CNY, representing an increase of about 59% [28]. - Sales expenses increased by 43.78% to ¥241,774.57 due to the addition of new sales personnel [14]. - Other income increased by 269.60% to ¥275,554.32, attributed to increased VAT deductions [14].

上会会计师事务所（特殊普通合伙） 中国 上海 ·计师 李 务 所（特殊善通合伙） ilied 9 ublic Accountants (Shecial Sieneral Pantnershib) 浙江海昇药业股份有限公司 浙江海昇药业股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审核报告 上会师报字(2024)第 5048 号 我们的责任是在执行审核工作的基础上对汇总表发表专项审核意见。 我们按照中国注册会计师审计准则的相关规定执行了审核工作。中国注册会计 师审计准则要求我们遵循中国注册会计师职业道德守则,计划和执行审核工作对汇 总表是否不存在重大错报获取合理保证。在审核的过程中,我们实施了包括检查会 计记录、重新计算相关项目金额等我们认为必要的程序。我们相信,我们的审核工 作为发表审核意见提供了合理的基础。 计师 李 务所（特殊善通合伙） tilied Public Accountants (Shecial Seneval Partnership) 我们认为，贵公司管理层编制的汇总表在所有重大方面符合《上市公司监管指 引第 8 号一上市公司资金往来、对外担保的监管要求》(证监会公告（20 ...

浙江海昇药业股份有限公司 审计报告 上会师报字(2024)第 5047 号 上会会计师事务所（特殊普通合伙） 中国 上海 ·计师 李今所(特殊普通台 lic Scountants (Shecial Seneval Par 审计报告 上会师报字(2024)第 5047 号 浙江海昇药业股份有限公司全体股东: 一、审计意见 我们审计了浙江海昇药业股份有限公司(以下简称"海昇药业公司")财务报表, 包括 2023 年 12 月 31 日的资产负债表, 2023 年度的利润表、现金流量表、所有者权 益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公 允反映了海昇药业公司 2023 年 12 月 31 日的财务状况以及 2023 年度的经营成果和现 金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册 会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照 中国注册会计师职业道德守则,我们独立于海昇药业公司,并履行了职业道德方面 的其他责任。我们相信,我们获取的审计证据是充分、适当的,为发表审计意见提 ...

长江证券承销保荐有限公司 关于浙江海昇药业股份有限公司 预计 2024 年日常性关联交易的核查意见 长江证券承销保荐有限公司（以下简称"长江保荐"或"保荐机构"）为浙 江海昇药业股份有限公司（以下简称"海昇药业"或"公司"）向不特定对象公 开发行股票并在北京证券交易所（以下简称"北交所"）上市的保荐机构。根据 《北京证券交易所上市公司持续监管办法（试行）》《北京证券交易所证券发行 上市保荐业务管理细则》《北京证券交易所股票上市规则（试行）》等有关规定， 对海昇药业预计 2024 年日常性关联交易情况进行核查，具体情况如下： 一、日常性关联交易的预计情况 | | | 单位：元 | | | | --- | --- | --- | --- | --- | | | 主要交 | 预计 2024 | 2023 年关 | 预计金额与上一 | | 关联交易类别 | 易内容 | 年发生金额 | 联方实际 | 年度实际发生金 | | | | | 发生金额 | 额差异较大原因 | | 购买原材料、燃料和动力、接受劳 务 | - | - - | | | | 出售产品、商品、提供劳务 | - | - - | | | | 委托关联人销售 ...